Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $59.60.

A number of research firms have recently weighed in on ORKA. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Piper Sandler initiated coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 13th. Finally, Barclays increased their target price on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, March 13th.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $38.91 on Friday. The firm has a market capitalization of $1.93 billion, a PE ratio of -20.92 and a beta of -0.38. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $42.88. The business’s fifty day moving average price is $34.24 and its two-hundred day moving average price is $28.47.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.16. Equities research analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the transaction, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC acquired a new stake in Oruka Therapeutics during the third quarter valued at approximately $25,640,000. Fairmount Funds Management LLC lifted its position in shares of Oruka Therapeutics by 9.9% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Financial Enhancement Group LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth $296,000. Finally, B Group Inc. raised its position in shares of Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after purchasing an additional 16,785 shares during the period. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.